Tenon Medical, Inc.
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
TNON$1.640.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (In thousands, except share data)
(In thousands, except share data)
| March 31, | December31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $4,607 | $3,756 |
| Accounts receivable, net | 1,969 | 1,698 |
| Inventory | 806 | 1,054 |
| Prepaid expenses and other current assets | 238 | 260 |
| Total current assets | 7,620 | 6,768 |
| Property and equipment, net | 901 | 918 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 1,389 | 131 |
| Intangible assets, net | 470 | 485 |
| Goodwill | 2,407 | 2,407 |
| TOTAL ASSETS | $12,838 | $10,760 |
| Liabilities and Stockholders’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $646 | $845 |
| Accrued expenses | 1,774 | 1,637 |
| Current portion of accrued commissions | 686 | 590 |
| Current portion of operating lease liability | 211 | 141 |
| Convertible notes | 3,480 | — |
| Derivative liability | 608 | — |
| Total current liabilities | 7,405 | 3,213 |
| Accrued commissions, net of current portion | 1,392 | 1,514 |
| Operating lease liability, net of current portion | 1,186 | — |
| Contingent consideration | 960 | 993 |
| Total liabilities | 10,943 | 5,720 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at March 31, 2026 and December 31, 2025; 204,159 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 2,622 | 2,622 |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at March 31, 2026 and December 31, 2025; 86,454 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 452 | 452 |
| Common stock, $0.001 par value; 130,000,000 shares authorized at March 31, 2026 and December 31, 2025; 11,296,378 and 10,851,273 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 83,588 | 83,257 |
| Accumulated deficit | (84,778) | (81,302) |
| Total stockholders’ equity | 1,895 | 5,040 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $12,838 | $10,760 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.